EU H2020 Project "FASNAGEL (NOVEL THERAPEUTIC NANOHYDROGEL FOR ACUTE AND CHRONIC PAIN TREATMENT TARGETED..)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/216901/index.html
-1	/open-h2020/projects/220338/index.html
-2	/open-consip/fornitori/2015/profilo-02604200424/index.html
-3	/open-consip/fornitori/2014/profilo-01074410513/index.html
-4	/open-consip/fornitori/2014/profilo-07170860725/index.html
-5	/open-h2020/per-topic/huntsman/list/index.html

FasNaGel project word cloud

Explore the words cloud of the FasNaGel project. It provides you a very rough idea of what is the project "FasNaGel" about.

100 started coming enormous time pain plane effectiveness first provides worldwide imed 20 huge absences chronic acid surgery thorough start euros market unemployment hydrogel prematurely estimates team personal reduce negative injectable post perform total 271 mill exit deducting sme 149 labour works world prevent staff operative few productivity 30 feasibility policies direct size biodegradable treatment indirect days made carrier quality population people 80 wrongly consists functional sickness track suffers medicines medical life containing marketing chronification 60 recovery greatest commercialization losses professional billion disorders inflammatory med nanostructured 102 porous depression fast report multiply patients healthcare 2014 drug anti hyaluronic validation biocompatible acute properly fasnagel gdp disability steroidal nanomedicinal

Project "FasNaGel" data sheet

The following table provides information about the project.

Coordinator	I+MED S.COOP. PEQUENA Organization address address: CALLE ALBERT EINSTEIN 15 city: VITORIA-GASTEIZ postcode: 1510 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	https://imasmed.com/portfolio-items/programas-investigacion/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-06-01 to 2018-11-30

#	participants	country	role	EC contrib. [€]
1	I+MED S.COOP. PEQUENA	ES (VITORIA-GASTEIZ)	coordinator	50˙000.00

I+MED S.COOP. PEQUENA

ES (VITORIA-GASTEIZ)

coordinator

50˙000.00

Project objective

Worldwide chronic pain conditions are by far the greatest cause of disability. It has an enormous negative impact on quality of life and on personal and professional plane. Chronic pain is an important cause of depression, more sickness absences at work, productivity losses, unemployment, etc.). Chronic pain is one of the major reasons (30%) why people exit the labour market prematurely. 20% of current population in Europe suffers from chronic pain (102 mill.) and up to 50 % of that pain comes from wrongly treated acute post-operative pain. The total direct and indirect healthcare costs for chronic pain disorders in Member States have an EU average of 2.4 % of GDP and a cost of 271 billion euros per year. When acute pain is not properly treated in the first few days, it can become chronic. About 40-60% of patients report pain chronification after surgery. Current medicines do not prevent chronic pain from the start and have side effects. “Fast track” approaches have started to take the lead in pain management policies. Based on these approaches I Med´s team works since 2014 in the development of FasNaGel, a new nanomedicinal product, unique in the world. It consists of a biocompatible and biodegradable injectable carrier, made of porous nanostructured hyaluronic acid hydrogel containing a non-steroidal anti-inflammatory drug that i) efficiently, provides a 100% of functional recovery after surgery in one third of the time, ii) is easy-to-use by medical staff, and the most important iii) increases by 80% the treatment effectiveness. FasNaGel will reduce the overall treatment costs in Europe, deducting indirect costs coming from acute pain up to €149 billion. The objective of this proposal is to be able to perform a thorough feasibility study for the validation of the production and commercialization of this novel product. FasNaGel marketing will have a huge of a SME such as iMed, who estimates to multiply the team size by 8 in 7 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FASNAGEL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FASNAGEL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat